STOCK TITAN
  1. Home
  2. News
  3. CAPR

Capricor Therapeutics Inc - CAPR STOCK NEWS

Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.

Capricor Therapeutics Inc (NASDAQ: CAPR) is a clinical-stage biotechnology leader advancing novel cell and exosome-based therapies for rare diseases. This dedicated news hub provides investors and researchers with essential updates on therapeutic developments, regulatory milestones, and scientific advancements.

Discover comprehensive coverage of CAP-1002 clinical progress for Duchenne muscular dystrophy, StealthXTM platform innovations, and strategic partnerships driving next-generation treatments. Our curated repository ensures access to verified press releases and objective reporting on critical developments in cardiac cell therapies and exosome delivery systems.

Key updates include clinical trial phases, peer-reviewed research publications, manufacturing advancements, and regulatory interactions. Bookmark this page for real-time tracking of Capricor's progress in redefining regenerative medicine through rigorous scientific validation and targeted therapeutic approaches.

News

Capricor Therapeutics Announces $23 Million Registered Direct Offering

Rhea-AI Summary
Capricor Therapeutics announces definitive agreements for the issuance and sale of 4,935,621 shares of common stock in a registered direct offering with an expected gross proceeds of approximately $23 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.24%
Tags
offering
-
News

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

Rhea-AI Summary
Capricor Therapeutics receives positive FDA feedback on trial design and timeline for CAP-1002 in treating DMD, confirming path towards BLA submission. Company on track to complete HOPE-3 enrollment and report interim analysis in Q4 2023. Plans to submit BLA in 2025. Topline data expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.24%
Tags
none
-
News

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

Rhea-AI Summary
Capricor Therapeutics appoints Michael Kelliher to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
management
News

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Capricor Therapeutics presented positive two-year data from their HOPE-2 open label extension study for CAP-1002 in patients with Duchenne Muscular Dystrophy (DMD). The results showed evidence of skeletal and cardiac functional improvements, supporting the potential long-term benefit of CAP-1002 treatment. They also held a clinical meeting with the FDA to discuss the results and the pathway towards a potential Biologics License Application (BLA) submission. Enrollment in their Phase 3 HOPE-3 trial is progressing well, with plans to complete enrollment and report interim analysis in Q4 2023. Capricor plans to submit data from the ongoing HOPE-2-OLE study at a medical meeting in Q4 2023. They completed construction of their San Diego GMP manufacturing facility and plan to have commercial-scale GMP CAP-1002 clinical doses available in Q3 2023. Capricor's cash position as of June 30, 2023, was approximately $37.8 million. They believe their available cash will be sufficient to cover expenses and capital requirements through Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.66%
Tags
earnings
-
News

Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

Rhea-AI Summary
Capricor Therapeutics (NASDAQ: CAPR) will release its financial results for the second quarter ended June 30, 2023, after the market close on August 7, 2023. A webcast and conference call will be hosted at 4:30 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences earnings
-
News

Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
management
News

Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
-
News

Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
conferences
News

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
Stock CAPR logo
Capricor Therapeutics Inc

Nasdaq:CAPR

CAPR Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CAPR Stock Data

513.86M
38.00M
16.84%
38.26%
17.96%
Biotechnology
Pharmaceutical Preparations
Link
United States
BEVERLY HILLS